Exelixis (EXEL) stock: analyst price target and their real reliability
Live quote · data updated Aug 28, 2026
Exelixis · Health Care · ref. ETF XLV · 71 calls · price $55.26
What the company does: Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
📈 Exelixis (EXEL) stock price
$55.26+45.8% over range
Aug 28, 25low $34.54 · high $57.1Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
27% recommend buying · 11 analysts
📊 JPI status : Exelixis is no longer in our current JPI rankings, but appeared in the past (2022) — its upside may be behind it. See the stocks picked in 2022 →
⚠️ The stock trades above the median target: it has beaten expectations. The “Hold” reflects conviction on the company, but the remaining quantified upside is low/negative.
🎯 EXEL price target & analyst consensus — price $55.26
The price target · all analysts combined (11 targets)
Highest target · 1 firm of 11$56+1.3%
Median target · of 11 targets$52-5.9%
Lowest target · 1 firm of 11$46-16.8%
Current price$55.26
Where these 11 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price
19%
$56
Below
1091%
$46 ↔ $55
⭐ What the most reliable analysts say
· those who beat their sector, targets replayed on real prices
⭐ The most reliable of them, either direction: HC Wainwright & Co. — 70% of its targets hit on this sector (238 calls tested). It aims for $56 (+1.3 %), call made on July 3, 2026, maturing on July 3, 2027 (56 d ago).
The 6 reliable analysts
$51.50-6.8 %
The 5 other firms
$54-2.3 %
How to read it: the 6 reliable firms are not filtered by optimism — 1 aim above the price, 5 below, hence their $51.50 median. “The 5 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 11 ratings (last 6 months)
Strong Buy00%
Buy327%
Hold873%
Sell00%
Strong Sell00%
Go deeper on the analysts
🎯 EXEL price target all
All 12 calls, one by one, with our verdict on each firm.
→ See all 12 targets, analyst by analyst💡 The best analysts on EXEL most reliable
The case for and against, with the numbers, per those who've been right on the stock.
→ Should you invest in EXEL? The case for & againstAll analysts (the consensus) · vs · the best (those who've been right)
💬 A question about Exelixis? The JPI assistant answers using our backtest data.
📈 Exelixis fundamentals: valuation, margins & growth › open the full page
P/E 17.7Net margin 35.3 %Revenue growth +10.6 %Cheap for the growth
Revenue, net income and margin per year
Revenue Net income · hover a bar for details
2022
marg. 11 %
2023
Rev +14%Profit +14%
2024
Rev +18%Profit +151%
2025
Rev +7%Profit +50%
🔎 Detailed analyses
🏛️ Which US Congress members hold Exelixis (EXEL)?
1 Congress member has disclosed EXEL buys. Click a highlighted name to see their track record (do they beat the S&P 500?).
Donna Shalala 2× · 59%
✅ Historical analyst reliability on EXEL
Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.
| Firm ↕ | % right i ↕ | Gain vs sector i ↕ | Calls i ↕ |
|---|---|---|---|
| TD Cowen ↗ | 100% | +52.1% | 2 |
| B of A Securities ↗ | 100% | +35.1% | 2 |
| JMP Securities | 100% | +34.6% | 20 |
| Citigroup ↗ | 100% | +30.4% | 3 |
| Guggenheim ↗ | 100% | +29.6% | 8 |
| Wells Fargo ↗ | 100% | +24.9% | 2 |
| EF Hutton | 100% | +24.8% | 7 |
| Barclays ↗ | 100% | +24.7% | 3 |
| Credit Suisse | 100% | +12.6% | 2 |
| Needham ↗ | 100% | +5.8% | 3 |
See the other 10 firms
| Maxim Group | 50% | -27.2% | 2 |
| Piper Sandler ↗ | 50% | -3.8% | 8 |
| BMO Capital ↗ | 50% | +2.0% | 2 |
| SunTrust Robinson Humphrey | 50% | +17.3% | 2 |
| Oppenheimer ↗ | 56% | +5.6% | 9 |
| Stifel ↗ | 75% | +127.7% | 4 |
| HC Wainwright & Co. ↗ | 79% | +22.3% | 14 |
| Morgan Stanley ↗ | 80% | +23.0% | 5 |
| RBC Capital ↗ | 83% | +24.5% | 12 |
| Truist Securities ↗ | 89% | +22.5% | 9 |
📊 What $1,000 invested in Exelixis would be worth › open the full page
In short — $1,000 invested in Exelixis 10 years ago would be worth $9,647 today, i.e. +25%/yr on average. Best year: 2016 (+164%), worst: 2018 (-35%). Price performance, excluding dividends.
If I'd invested $1,000 in Exelixis
| Investment | Worth today | Gain |
|---|---|---|
| 1 years ago | $1,634 | +63% |
| 3 years ago | $3,392 | +239% |
| 5 years ago | $2,711 | +171% |
Return by year (Exelixis)
| Year | Return | $1,000 invested at year start |
|---|---|---|
| 2026 (YTD) | +24% | $1,241 (+24%) |
| 2025 | +32% | $1,634 (+63%) |
| 2024 | +39% | $2,268 (+127%) |
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.
📰 Recent news on Exelixis
Loading news…
📋 All analyst calls on EXEL
Filtered on — · ✕ show all
BMO Capital ↗
Aug 19, 26
■ Market Perform neutral · not a buy · 🎯$54
Price at call : $54.39 — gap to target -1%
Today : $55.26 — gap to target -2%
🎯 on EXEL : no call matured yet · 📊 on Health : 45.7% · +6.4% (35 calls)
in progress (365j)
matures : Aug 19, 27
matures : Aug 19, 27
Truist Securities ↗
Aug 6, 26
■ Hold neutral · not a buy · 🎯$52
Price at call : $54.07 — gap to target -4%
Today : $55.26 — gap to target -6%
🎯 on EXEL : 100% (1 call matured) · 📊 on Health : 58.7% · +5.8% (109 calls)
in progress (365j)
matures : Aug 6, 27
matures : Aug 6, 27
■ Hold neutral · not a buy · 🎯$51
Price at call : $54.07 — gap to target -6%
Today : $55.26 — gap to target -8%
🎯 on EXEL : no call matured yet · 📊 on Health : 48% · +12.4% (98 calls)
in progress (365j)
matures : Aug 6, 27
matures : Aug 6, 27
Morgan Stanley ↗
Jul 23, 26
■ Equal-Weight neutral · not a buy · 🎯$53
Price at call : $55.37 — gap to target -4%
Today : $55.26 — gap to target -4%
🎯 on EXEL : 100% (1 call matured) · 📊 on Health : 41.3% · -1.5% (196 calls)
in progress (365j)
matures : Jul 23, 27
matures : Jul 23, 27
■ Equal-Weight neutral · not a buy · 🎯$49
Price at call : $55.77 — gap to target -12%
Today : $55.26 — gap to target -11%
🎯 on EXEL : no call matured yet · 📊 on Health : 47.9% · +1.6% (194 calls)
in progress (365j)
matures : Jul 14, 27
matures : Jul 14, 27
Wells Fargo ↗
Jul 13, 26
■ Equal-Weight neutral · not a buy · 🎯$49
Price at call : $55.77 — gap to target -12%
Today : $55.26 — gap to target -11%
🎯 on EXEL : no call matured yet · 📊 on Health : 47% · +4.6% (149 calls)
in progress (365j)
matures : Jul 13, 27
matures : Jul 13, 27
RBC Capital ↗
Jul 7, 26
■ Sector Perform neutral · not a buy · 🎯$46
Price at call : $56.11 — gap to target -18%
Today : $55.26 — gap to target -17%
🎯 on EXEL : no call matured yet · 📊 on Health : 49.2% · +7.0% (195 calls)
in progress (365j)
matures : Jul 7, 27
matures : Jul 7, 27
Truist Securities ↗
Jul 7, 26
■ Hold neutral · not a buy · 🎯$56
Price at call : $57.08 — gap to target -2%
Today : $55.26 — gap to target +1%
🎯 on EXEL : 100% (1 call matured) · 📊 on Health : 58.7% · +5.8% (109 calls)
in progress (365j)
matures : Jul 7, 27
matures : Jul 7, 27
See the other 63 calls, newest to oldest
■ Neutral neutral · not a buy · 🎯$52
Price at call : $55.85 — gap to target -7%
Today : $55.26 — gap to target -6%
🎯 on EXEL : no call matured yet · 📊 on Health : 49.6% · +18.1% (119 calls)
in progress (365j)
matures : Jul 2, 27
matures : Jul 2, 27
HC Wainwright & Co. ↗
Jul 2, 26
▲ Buy · 🎯$56
Price at call : $55.85 — upside +0%
Today : $55.26 — upside +1%
🎯 on EXEL : 92% (12 calls matureds) · 📊 on Health : 68.1% · +24.0% (238 calls)
in progress (365j)
matures : Jul 2, 27
matures : Jul 2, 27
Truist Securities ↗
Jun 25, 26
■ Hold neutral · not a buy · 🎯$54
Price at call : $54.77 — gap to target -1%
Today : $55.26 — gap to target -2%
🎯 on EXEL : 100% (1 call matured) · 📊 on Health : 58.7% · +5.8% (109 calls)
in progress (365j)
matures : Jun 25, 27
matures : Jun 25, 27
Citizens
Jun 24, 26
▲ Market Outperform · 🎯$55
Price at call : $52.87 — upside +4%
Today : $55.26 — upside -0%
🎯 on EXEL : no call matured yet · 📊 unranked overall
in progress (365j)
matures : Jun 24, 27
matures : Jun 24, 27
HC Wainwright & Co. ↗
May 7, 26
▲ Buy · 🎯$56
Price at call : $46.21 — upside +21%
Today : $55.26 — upside +1%
🎯 on EXEL : 92% (12 calls matureds) · 📊 on Health : 68.1% · +24.0% (238 calls)
in progress (365j)
matures : May 7, 27
matures : May 7, 27
▲ Buy · 🎯$55
Price at call : $46.21 — upside +19%
Today : $55.26 — upside -0%
🎯 on EXEL : no call matured yet · 📊 on Health : 53.8% · +17.8% (26 calls)
in progress (365j)
matures : May 6, 27
matures : May 6, 27
Morgan Stanley ↗
May 6, 26
■ Equal-Weight neutral · not a buy · 🎯$50
Price at call : $46.21 — gap to target +8%
Today : $55.26 — gap to target -10%
🎯 on EXEL : 100% (1 call matured) · 📊 on Health : 41.3% · -1.5% (196 calls)
in progress (365j)
matures : May 6, 27
matures : May 6, 27
■ Hold neutral · not a buy · 🎯$47
Price at call : $46.21 — gap to target +2%
Today : $55.26 — gap to target -15%
🎯 on EXEL : no call matured yet · 📊 on Health : 48% · +12.4% (98 calls)
in progress (365j)
matures : May 6, 27
matures : May 6, 27
Wells Fargo ↗
May 6, 26
■ Equal-Weight neutral · not a buy · 🎯$40
Price at call : $46.21 — gap to target -13%
Today : $55.26 — gap to target -28%
🎯 on EXEL : no call matured yet · 📊 on Health : 47% · +4.6% (149 calls)
in progress (365j)
matures : May 6, 27
matures : May 6, 27
■ Equal-Weight neutral · not a buy · 🎯$45
Price at call : $45.89 — gap to target -2%
Today : $55.26 — gap to target -19%
🎯 on EXEL : no call matured yet · 📊 on Health : 47.9% · +1.6% (194 calls)
in progress (365j)
matures : Apr 20, 27
matures : Apr 20, 27
RBC Capital ↗
Mar 2, 26
■ Sector Perform neutral · not a buy · 🎯$43
Price at call : $40.74 — gap to target +6%
Today : $55.26 — gap to target -22%
🎯 on EXEL : no call matured yet · 📊 on Health : 49.2% · +7.0% (195 calls)
in progress (365j)
matures : Mar 2, 27
matures : Mar 2, 27
HC Wainwright & Co. ↗
Feb 12, 26
▲ Buy · 🎯$54
Price at call : $42.7 — upside +26%
Today : $55.26 — upside -2%
🎯 on EXEL : 92% (12 calls matureds) · 📊 on Health : 68.1% · +24.0% (238 calls)
in progress (365j)
matures : Feb 12, 27
matures : Feb 12, 27
RBC Capital ↗
Feb 11, 26
■ Sector Perform neutral · not a buy · 🎯$46
Price at call : $42.7 — gap to target +8%
Today : $55.26 — gap to target -17%
🎯 on EXEL : no call matured yet · 📊 on Health : 49.2% · +7.0% (195 calls)
in progress (365j)
matures : Feb 11, 27
matures : Feb 11, 27
■ Hold neutral · not a buy · 🎯$44
Price at call : $42.7 — gap to target +3%
Today : $55.26 — gap to target -20%
🎯 on EXEL : no call matured yet · 📊 on Health : 48% · +12.4% (98 calls)
in progress (365j)
matures : Feb 11, 27
matures : Feb 11, 27
Wells Fargo ↗
Feb 11, 26
■ Equal-Weight neutral · not a buy · 🎯$35
Price at call : $42.7 — gap to target -18%
Today : $55.26 — gap to target -37%
🎯 on EXEL : no call matured yet · 📊 on Health : 47% · +4.6% (149 calls)
in progress (365j)
matures : Feb 11, 27
matures : Feb 11, 27
■ Equal-Weight neutral · not a buy · 🎯$44
Price at call : $42.65 — gap to target +3%
Today : $55.26 — gap to target -20%
🎯 on EXEL : no call matured yet · 📊 on Health : 47.9% · +1.6% (194 calls)
in progress (365j)
matures : Feb 4, 27
matures : Feb 4, 27
HC Wainwright & Co. ↗
Feb 3, 26
▲ Buy · 🎯$52
Price at call : $42.59 — upside +22%
Today : $55.26 — upside -6%
🎯 on EXEL : 92% (12 calls matureds) · 📊 on Health : 68.1% · +24.0% (238 calls)
in progress (365j)
matures : Feb 3, 27
matures : Feb 3, 27
Morgan Stanley ↗
Feb 2, 26
■ Equal-Weight neutral · not a buy · 🎯$49
Price at call : $42.59 — gap to target +15%
Today : $55.26 — gap to target -11%
🎯 on EXEL : 100% (1 call matured) · 📊 on Health : 41.3% · -1.5% (196 calls)
in progress (365j)
matures : Feb 2, 27
matures : Feb 2, 27
HC Wainwright & Co. ↗
Jan 27, 26
▲ Buy · 🎯$52
Price at call : $43.74 — upside +19%
Today : $55.26 — upside -6%
🎯 on EXEL : 92% (12 calls matureds) · 📊 on Health : 68.1% · +24.0% (238 calls)
in progress (365j)
matures : Jan 27, 27
matures : Jan 27, 27
HC Wainwright & Co. ↗
Jan 8, 26
▲ Buy · 🎯$52
Price at call : $44.04 — upside +18%
Today : $55.26 — upside -6%
🎯 on EXEL : 92% (12 calls matureds) · 📊 on Health : 68.1% · +24.0% (238 calls)
in progress (365j)
matures : Jan 8, 27
matures : Jan 8, 27
Morgan Stanley ↗
Jan 8, 26
■ Equal-Weight neutral · not a buy · 🎯$48
Price at call : $44.15 — gap to target +9%
Today : $55.26 — gap to target -13%
🎯 on EXEL : 100% (1 call matured) · 📊 on Health : 41.3% · -1.5% (196 calls)
in progress (365j)
matures : Jan 8, 27
matures : Jan 8, 27
■ Neutral neutral · not a buy · 🎯$40
Price at call : $40.81 — gap to target -2%
Today : $55.26 — gap to target -28%
🎯 on EXEL : no call matured yet · 📊 on Health : 49.6% · +18.1% (119 calls)
in progress (365j)
matures : Nov 6, 26
matures : Nov 6, 26
▲ Buy · 🎯$51
Price at call : $40.8 — upside +25%
Today : $55.26 — upside -8%
🎯 on EXEL : no call matured yet · 📊 on Health : 53.8% · +17.8% (26 calls)
in progress (365j)
matures : Nov 5, 26
matures : Nov 5, 26
Morgan Stanley ↗
Nov 5, 25
▲ Overweight · 🎯$45
Price at call : $40.8 — upside +10%
Today : $55.26 — upside -19%
🎯 on EXEL : 100% (1 call matured) · 📊 on Health : 41.3% · -1.5% (196 calls)
in progress (365j)
matures : Nov 5, 26
matures : Nov 5, 26
■ Equal-Weight neutral · not a buy · 🎯$41
Price at call : $40.8 — gap to target +0%
Today : $55.26 — gap to target -26%
🎯 on EXEL : no call matured yet · 📊 on Health : 47.9% · +1.6% (194 calls)
in progress (365j)
matures : Nov 5, 26
matures : Nov 5, 26
HC Wainwright & Co. ↗
Nov 5, 25
▲ Buy · 🎯$49
Price at call : $40.8 — upside +20%
Today : $55.26 — upside -11%
🎯 on EXEL : 92% (12 calls matureds) · 📊 on Health : 68.1% · +24.0% (238 calls)
in progress (365j)
matures : Nov 5, 26
matures : Nov 5, 26
Guggenheim ↗
Nov 3, 25
■ Neutral neutral · not a buy
🎯 on EXEL : 100% (8 calls matureds) · 📊 on Health : 69.2% · +19.9% (52 calls)
in progress (365j)
matures : Nov 3, 26
matures : Nov 3, 26
Morgan Stanley ↗
Oct 21, 25
▲ Overweight · 🎯$44
Price at call : $36.08 — upside +22%
Today : $55.26 — upside -20%
🎯 on EXEL : 100% (1 call matured) · 📊 on Health : 41.3% · -1.5% (196 calls)
in progress (365j)
matures : Oct 21, 26
matures : Oct 21, 26
RBC Capital ↗
Oct 21, 25
■ Sector Perform neutral · not a buy · 🎯$45
Price at call : $36.08 — gap to target +25%
Today : $55.26 — gap to target -19%
🎯 on EXEL : no call matured yet · 📊 on Health : 49.2% · +7.0% (195 calls)
in progress (365j)
matures : Oct 21, 26
matures : Oct 21, 26
Wells Fargo ↗
Oct 21, 25
■ Equal-Weight neutral · not a buy · 🎯$30
Price at call : $36.13 — gap to target -17%
Today : $55.26 — gap to target -46%
🎯 on EXEL : no call matured yet · 📊 on Health : 47% · +4.6% (149 calls)
in progress (365j)
matures : Oct 21, 26
matures : Oct 21, 26
Leerink Partners ↗
Oct 21, 25
▲ Outperform · 🎯$48
Price at call : $36.13 — upside +33%
Today : $55.26 — upside -13%
🎯 on EXEL : no call matured yet · 📊 on Health : 54.5% · +10.0% (11 calls)
in progress (365j)
matures : Oct 21, 26
matures : Oct 21, 26
Morgan Stanley ↗
Sep 17, 25
▲ Overweight · 🎯$50
Price at call : $40.45 — upside +24%
Today : $55.26 — upside -10%
🎯 on EXEL : 100% (1 call matured) · 📊 on Health : 41.3% · -1.5% (196 calls)
in progress (365j)
matures : Sep 17, 26
matures : Sep 17, 26
Goldman Sachs ↗
Sep 17, 25
▲ Buy · 🎯$47
Price at call : $40.45 — upside +16%
Today : $55.26 — upside -15%
🎯 on EXEL : no call matured yet · 📊 on Health : 57.9% · +13.8% (107 calls)
in progress (365j)
matures : Sep 17, 26
matures : Sep 17, 26
■ Equal-Weight neutral · not a buy · 🎯$40
Price at call : $40.44 — gap to target -1%
Today : $55.26 — gap to target -28%
🎯 on EXEL : no call matured yet · 📊 on Health : 47.9% · +1.6% (194 calls)
in progress (365j)
matures : Sep 17, 26
matures : Sep 17, 26
HC Wainwright & Co. ↗
Aug 12, 25
▲ Buy · 🎯$46
Price at call : $37.95 — upside +21%
Today : $55.26 — upside -17%
Expected +21% · Actual +33% · Reason (≥ +15%) : ✓ Yes
🎯 on EXEL : 92% (12 calls matureds) · 📊 on Health : 68.1% · +24.0% (238 calls)
+32.8%
stock +33% · XLV +28%
matured Aug 12, 26
■ Neutral neutral · not a buy · 🎯$38
Price at call : $36.22 — gap to target +5%
Today : $55.26 — gap to target -31%
🎯 on EXEL : no call matured yet · 📊 on Health : 49.6% · +18.1% (119 calls)
in progress (365j)
matures : Jul 30, 26
matures : Jul 30, 26
Truist Securities ↗
Jul 29, 25
▲ Buy · 🎯$49
Price at call : $36.85 — upside +33%
Today : $55.26 — upside -11%
Expected +33% · Actual +52% · Reason (≥ +15%) : ✓ Yes
🎯 on EXEL : 100% (1 call matured) · 📊 on Health : 58.7% · +5.8% (109 calls)
+51.9%
stock +52% · XLV +22%
matured Jul 29, 26
Morgan Stanley ↗
Jul 29, 25
▲ Overweight · 🎯$46
Price at call : $36.85 — upside +25%
Today : $55.26 — upside -17%
Expected +25% · Actual +52% · Reason (≥ +15%) : ✓ Yes
🎯 on EXEL : 100% (1 call matured) · 📊 on Health : 41.3% · -1.5% (196 calls)
+51.9%
stock +52% · XLV +22%
matured Jul 29, 26
RBC Capital ↗
Jul 29, 25
■ Sector Perform neutral · not a buy · 🎯$45
Price at call : $36.85 — gap to target +22%
Today : $55.26 — gap to target -19%
🎯 on EXEL : no call matured yet · 📊 on Health : 49.2% · +7.0% (195 calls)
in progress (365j)
matures : Jul 29, 26
matures : Jul 29, 26
JMP Securities
Jul 29, 25
▲ Market Outperform · 🎯$50
Price at call : $36.85 — upside +36%
Today : $55.26 — upside -10%
Expected +36% · Actual +52% · Reason (≥ +15%) : ✓ Yes
🎯 on EXEL : 100% (1 call matured) · 📊 unranked overall
+51.9%
stock +52% · XLV +22%
matured Jul 29, 26
Guggenheim ↗
Jul 29, 25
▲ Buy · 🎯$45
Price at call : $36.85 — upside +22%
Today : $55.26 — upside -19%
Expected +22% · Actual +52% · Reason (≥ +15%) : ✓ Yes
🎯 on EXEL : 100% (8 calls matureds) · 📊 on Health : 69.2% · +19.9% (52 calls)
+51.9%
stock +52% · XLV +22%
matured Jul 29, 26
■ Hold neutral · not a buy · 🎯$41
Price at call : $36.94 — gap to target +11%
Today : $55.26 — gap to target -26%
🎯 on EXEL : no call matured yet · 📊 on Health : 48% · +12.4% (98 calls)
in progress (365j)
matures : Jul 29, 26
matures : Jul 29, 26
HC Wainwright & Co. ↗
Jun 30, 25
▲ Buy · 🎯$53
Price at call : $44.08 — upside +20%
Today : $55.26 — upside -4%
Expected +20% · Actual +23% · Reason (≥ +15%) : ✓ Yes
🎯 on EXEL : 92% (12 calls matureds) · 📊 on Health : 68.1% · +24.0% (238 calls)
+23.4%
stock +23% · XLV +18%
matured Jun 30, 26
HC Wainwright & Co. ↗
Jun 12, 25
▲ Buy · 🎯$47
Price at call : $41.78 — upside +12%
Today : $55.26 — upside -15%
Expected +12% · Actual +27% · Reason (≥ +15%) : ✓ Yes
🎯 on EXEL : 92% (12 calls matureds) · 📊 on Health : 68.1% · +24.0% (238 calls)
+27.2%
stock +27% · XLV +12%
matured Jun 12, 26
HC Wainwright & Co. ↗
Mar 27, 25
▲ Buy · 🎯$40
Price at call : $36.84 — upside +9%
Today : $55.26 — upside -28%
Expected +9% · Actual +13% · Reason (≥ +15%) : ✗ No
🎯 on EXEL : 92% (12 calls matureds) · 📊 on Health : 68.1% · +24.0% (238 calls)
+12.7%
stock +13% · XLV -1%
matured Mar 27, 26
HC Wainwright & Co. ↗
Feb 13, 25
▲ Buy · 🎯$40
Price at call : $34.49 — upside +16%
Today : $55.26 — upside -28%
Expected +16% · Actual +27% · Reason (≥ +15%) : ✓ Yes
🎯 on EXEL : 92% (12 calls matureds) · 📊 on Health : 68.1% · +24.0% (238 calls)
+27.3%
stock +27% · XLV +8%
matured Feb 13, 26
HC Wainwright & Co. ↗
Feb 13, 25
▲ Buy · 🎯$40
Price at call : $34.49 — upside +16%
Today : $55.26 — upside -28%
Expected +16% · Actual +27% · Reason (≥ +15%) : ✓ Yes
🎯 on EXEL : 92% (12 calls matureds) · 📊 on Health : 68.1% · +24.0% (238 calls)
+27.3%
stock +27% · XLV +8%
matured Feb 13, 26
Guggenheim ↗
Feb 12, 25
▲ Buy · 🎯$42
Price at call : $34.49 — upside +22%
Today : $55.26 — upside -24%
Expected +22% · Actual +27% · Reason (≥ +15%) : ✓ Yes
🎯 on EXEL : 100% (8 calls matureds) · 📊 on Health : 69.2% · +19.9% (52 calls)
+27.3%
stock +27% · XLV +8%
matured Feb 12, 26
HC Wainwright & Co. ↗
Jan 27, 25
▲ Buy · 🎯$40
Price at call : $32.73 — upside +22%
Today : $55.26 — upside -28%
Expected +22% · Actual +34% · Reason (≥ +15%) : ✓ Yes
🎯 on EXEL : 92% (12 calls matureds) · 📊 on Health : 68.1% · +24.0% (238 calls)
+33.6%
stock +34% · XLV +5%
matured Jan 27, 26
Guggenheim ↗
Jan 22, 25
▲ Buy
Actual +30% · Reason (≥ +15%) : ✓ Yes
🎯 on EXEL : 100% (8 calls matureds) · 📊 on Health : 69.2% · +19.9% (52 calls)
+29.7%
stock +30% · XLV +9%
matured Jan 22, 26
HC Wainwright & Co. ↗
Jan 10, 25
▲ Buy · 🎯$40
Price at call : $36.02 — upside +11%
Today : $55.26 — upside -28%
Expected +11% · Actual +22% · Reason (≥ +15%) : ✓ Yes
🎯 on EXEL : 92% (12 calls matureds) · 📊 on Health : 68.1% · +24.0% (238 calls)
+22.3%
stock +22% · XLV +13%
matured Jan 10, 26
Guggenheim ↗
Jan 7, 25
▲ Buy · 🎯$42
Price at call : $34.5 — upside +22%
Today : $55.26 — upside -24%
Expected +22% · Actual +28% · Reason (≥ +15%) : ✓ Yes
🎯 on EXEL : 100% (8 calls matureds) · 📊 on Health : 69.2% · +19.9% (52 calls)
+28.0%
stock +28% · XLV +13%
matured Jan 7, 26
Guggenheim ↗
Oct 30, 24
▲ Buy · 🎯$33
Price at call : $33.2 — upside -1%
Today : $55.26 — upside -40%
Expected -1% · Actual +16% · Reason (≥ +15%) : ✓ Yes
🎯 on EXEL : 100% (8 calls matureds) · 📊 on Health : 69.2% · +19.9% (52 calls)
+16.5%
stock +16% · XLV -2%
matured Oct 30, 25
HC Wainwright & Co. ↗
Sep 18, 24
▲ Buy · 🎯$29
Price at call : $26.82 — upside +8%
Today : $55.26 — upside -48%
Expected +8% · Actual +51% · Reason (≥ +15%) : ✓ Yes
🎯 on EXEL : 92% (12 calls matureds) · 📊 on Health : 68.1% · +24.0% (238 calls)
+50.8%
stock +51% · XLV -12%
matured Sep 18, 25
HC Wainwright & Co. ↗
May 3, 24
▲ Buy · 🎯$28
Price at call : $21.9 — upside +28%
Today : $55.26 — upside -49%
Expected +28% · Actual +82% · Reason (≥ +15%) : ✓ Yes
🎯 on EXEL : 92% (12 calls matureds) · 📊 on Health : 68.1% · +24.0% (238 calls)
+81.9%
stock +82% · XLV -2%
matured May 3, 25
Guggenheim ↗
Oct 11, 23
▲ Buy · 🎯$30
Price at call : $21.24 — upside +41%
Today : $55.26 — upside -46%
Expected +41% · Actual +23% · Reason (≥ +15%) : ✓ Yes
🎯 on EXEL : 100% (8 calls matureds) · 📊 on Health : 69.2% · +19.9% (52 calls)
+23.5%
stock +23% · XLV +19%
matured Oct 10, 24
HC Wainwright & Co. ↗
Sep 26, 23
▲ Buy · 🎯$28
Price at call : $21.75 — upside +29%
Today : $55.26 — upside -49%
Expected +29% · Actual +20% · Reason (≥ +15%) : ✓ Yes
🎯 on EXEL : 92% (12 calls matureds) · 📊 on Health : 68.1% · +24.0% (238 calls)
+19.8%
stock +20% · XLV +18%
matured Sep 25, 24
Guggenheim ↗
Sep 25, 23
▲ Buy · 🎯$30
Price at call : $21.75 — upside +38%
Today : $55.26 — upside -46%
Expected +38% · Actual +20% · Reason (≥ +15%) : ✓ Yes
🎯 on EXEL : 100% (8 calls matureds) · 📊 on Health : 69.2% · +19.9% (52 calls)
+19.8%
stock +20% · XLV +18%
matured Sep 24, 24
HC Wainwright & Co. ↗
Feb 18, 22
▲ Buy · 🎯$42
Price at call : $19.6 — upside +114%
Today : $55.26 — upside -24%
Expected +114% · Actual -11% · Reason (≥ +15%) : ✗ No
🎯 on EXEL : 92% (12 calls matureds) · 📊 on Health : 68.1% · +24.0% (238 calls)
-11.0%
stock -11% · XLV +2%
matured Feb 18, 23
Guggenheim ↗
Oct 15, 19
▲ Buy · 🎯$25
Price at call : $16.79 — upside +49%
Today : $55.26 — upside -55%
Expected +49% · Actual +40% · Reason (≥ +15%) : ✓ Yes
🎯 on EXEL : 100% (8 calls matureds) · 📊 on Health : 69.2% · +19.9% (52 calls)
+40.4%
stock +40% · XLV +18%
matured Oct 14, 20
Maxim Group
Nov 12, 13
▲ Buy
Actual -64% · Reason (≥ +15%) : ✗ No
🎯 on EXEL : 50% (2 calls matureds) · 📊 on Health : 0% · -39.1% (4 calls)
-63.6%
stock -64% · XLV +27%
matured Nov 12, 14
Maxim Group
May 28, 13
■ Hold neutral · not a buy
🎯 on EXEL : 50% (2 calls matureds) · 📊 on Health : 0% · -39.1% (4 calls)
in progress (365j)
matures : May 28, 14
matures : May 28, 14
Maxim Group
Nov 8, 12
▲ Buy · 🎯$6
Price at call : $4.58 — upside +31%
Today : $55.26 — upside -89%
Expected +31% · Actual +9% · Reason (≥ +15%) : ✗ No
🎯 on EXEL : 50% (2 calls matureds) · 📊 on Health : 0% · -39.1% (4 calls)
+9.2%
stock +9% · XLV +36%
matured Nov 8, 13
Frequently asked questions
Should I buy Exelixis stock?
This isn't buy advice. For Exelixis, the analyst consensus is "Hold", with an average price target of $52.00 (-6% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (2 calls tracked on Exelixis). We show the numbers — you decide.
Is it too late to buy Exelixis? How high can it go?
The most bullish analyst target on Exelixis is $56.00 (+1% above today's price); the average is $52.00. That's the upside they see. Check how reliable those analysts have actually been on Exelixis on our site before trusting it.
Is Exelixis still a good buy?
The most useful "opinion" isn't an opinion — it's a track record: 20 analysts have a real record on Exelixis, the best hitting 100% over 2 calls. Current consensus: "Hold". Make your call on data, not noise.
Should you invest in Exelixis? The case for and against
The arguments for and against, one by one, from the numbers: why invest in EXEL (and why hesitate).
What has Exelixis's past performance been?
Historical returns and a "how much if I had invested" calculator: EXEL performance & returns.
What is the best month to buy EXEL?
The 12 months ranked by the stock's past returns: best & worst month to buy EXEL.
BIIB 
VRTX 
UNH 
REGN 
EW 
SRPT 
VEEV 
BSX